Clinical need Enterra Medical offers Enterra Therapy for gastroparesis, a niche but high-need area with proven patient reach (over 15,000 implanted). This suggests sales opportunities in hospitals and specialty centers treating refractory nausea and vomiting where gain from device-based gastric electrical stimulation could be pursued.

Regulatory niche The therapy operates under a FDA humanitarian device exemption, highlighting a unique regulatory pathway and potential collaboration opportunities with centers serving eligible 18 to 70 year olds with drug-refractory gastroparesis, indicating targeted institutional sales and payer discussions.

Clinical science Continued emphasis on expanding clinical science presents openings for partnerships in clinical studies, post-market surveillance, and surgeon education programs to drive adoption and evidence generation in key medical centers.

Growth potential With revenue in the range of tens of millions and a relatively lean employee base, there is room to scale through strategic partnerships with larger medical device distributors, joint ventures, or hospital procurement programs to accelerate market penetration.

Technology stack Investments in cloud and data workflows (Microsoft Power Platform, AWS, Tableau) indicate readiness for digital enablement, suggesting sales opportunities around clinical data capture, patient outcomes analytics, and value-based contracting to demonstrate device effectiveness to payers and providers.